(E)-N-环丙基-1-(2-吡啶基)甲亚胺 | 121532-31-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: (E)-N-环丙基-1-(2-吡啶基)甲亚胺
• 英文名称: NC5H4-2-C(H)=N(c-Pr)
• 英文别名: cyclopropylpyridin-2-ylmethyleneamine；Cyclopropanamine, N-(2-pyridinylmethylene)-(9CI)；N-cyclopropyl-1-pyridin-2-ylmethanimine
• CAS: 121532-31-8
• 化学式: C₉H₁₀N₂
• 分子量: 146.192
• InChiKey: IKXXCWGFFYUSQP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  25.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  tetrakis(acetonitrile)copper(I) perchlorate 、 (E)-N-环丙基-1-(2-吡啶基)甲亚胺 以 乙腈 为溶剂， 以90%的产率得到bis(cyclopropylpyridin-2-ylmethyleneamine)copper(I) perchlorate
  参考文献：
  名称：

  Structure-dependent spectroscopic and redox properties of copper(I) complexes with bidentate iminopyridine ligands

  摘要：

  A series of iminopyridine ligands; cyclopropylpyridin-2-ylmethyleneamine (A), cyclopentylpyridin-2-ylmethyleneamine (B), cyclohexylpyridin-2-ylmethyleneamine (C), and cycloheptylpyridin-2-ylmethyleneamine, (D) and their copper(I) complexes, [Cu(L)(2)](+) (1a-1d) and [Cu(L)(PPh3)(2)](+) (2a-2d) have been synthesized and characterized by CHN analyses, H-1 NMR and IR and UV-Vis spectroscopy. Structures of 1a, 1b, 1c and 2a were determined by X-ray crystallography. The coordination polyhedron about the Cu-I center in the complexes is best described as a distorted tetrahedron. The dihedral angles between the least-squares planes of the chelate ligands show considerable variation from 86.1 degrees in 1a to 68.3 degrees in 1b, indicating the importance of packing forces in the crystalline environment. The UV-Vis spectra of the complexes are characterized by first metal to ligand charge transfer bands increasing in wavelength with increasing size of the ring substituents in the ligands, except for the cyclopropyl compounds (1a and 2a), in good agreement with the variation of the dihedral angles between the ligand planes. Cyclic voltammetry of the complexes indicates a quasireversible redox behavior for the complexes. The bulkier ligands (PPh3) inhibit the geometric distortion within the oxidized form and the redox potentials of complexes 2a-2d are shifted to more positive values, therefore. (C) 2009 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ica.2009.01.008
• 作为产物：
  描述：

  吡啶-2-甲醛 、 环丙胺 以 二氯甲烷 为溶剂， 反应 48.0h， 生成 (E)-N-环丙基-1-(2-吡啶基)甲亚胺
  参考文献：
  名称：

  亲脂性吡啶甲羧二胺铂（II）配合物的合成，表征和抗癌活性

  摘要：

  摘要我们从2-吡啶甲醛与相应的亲脂性伯胺的缩合反应中制得了11种吡啶甲二胺（N-N'R）。将这些配体添加到[PtCl 2（η2 -coe）] 2（coe =顺式环辛烯）中，得到中等至高产率的顺式-PtCl 2（N-N'R）（2a-k）型配合物。通过X射线衍射研究已经确认了N-丁基苯基衍生物（2h）的分子结构。2h晶体是单斜晶，在空间群P 2（1）/ c中a = 8.5414（9）A，b = 11.6774（12）A，c = 16.1235（16）A，β= 92.7610（10）°。检查所有铂配合物对两种人成胶质细胞瘤多形细胞系LN18和LN405的体外细胞毒性。比较了一种最具细胞毒性的化合物与顺铂的DNA结合特性，

  DOI：

  10.1016/j.poly.2015.07.039

文献信息

• Synthesis and characterization of two isomers of Os3(CO)10(C5H4N-2-C(H)NR) and the conversion to ortho-metallated HOs3(C5H3N-2-C(H)NR)(CO)9. Part III. X-ray Structure of HOs3(C5H3N-2-C(H)Ni-Pr)(CO)9
  作者：Robert Zoet、Gerard Van Koten、Kees Vrieze、Albert J.M. Duisenberg、Anthony L. Spek

  DOI：10.1016/s0020-1693(00)86014-4

  日期：1988.8

  Os3(CO)10(MeCN)2 reacts at room temperature in MeCN or toluene with R-Pyca† to yield two isomers of Os3(CO)10(R-Pyca) that differ in the bonding of the R-Pyca ligand to the Os3(CO)10 unit. In all cases Os3(CO)10(R-Pyca(4e)) (isomer A; 4a: R = c-Pr, 4b: R = i-Pr, 4c: R = neo-Pent, 4d: R = t-Bu), containing a chelating 4e donating R-Pyca ligand and three OsS bonds, could be isolated. In the case of R

  Os 3（CO）10（MeCN）2在室温下在MeCN或甲苯中与R-Pyca†反应，生成Os 3（CO）10（R-Pyca）的两种异构体，它们的R-Pyca配体键合不同到Os 3（CO）10单元。在所有情况下Os 3（CO）10（R-Pyca（4e））（异构体A; 4a：R = c-Pr，4b：R = i-Pr，4c：R = neo-Pent，4d：R = t -Bu），其中含有螯合的4e供体R-Pyca配体和三个OsS键，可以分离出来。在R = c-Pr和R = i-Pr的情况下Os 3（CO）10（R-Pyca（6e））（异构体B; 5a：R = c-Pr，5b：R = i-Pr），其中仅存在两个OsS键，并且R-Pyca配体作为6e供体配体键合桥接两个未键合的Os原子，可以作为次要产物分离出来。
• Anthranilamides and methods of their use
  申请人：——

  公开号：US20030187033A1

  公开（公告）日：2003-10-02

  The present invention is related to anthranilamides of formula I, 1 in which R(1) to R(7) have the meanings indicated herein, a process for their preparation, their use as medicaments, and pharmaceutical preparations containing them. The compounds act on the Kv1.5 potassium channel and inhibit a potassium current which is referred to as the ultra-rapidly activating delayed rectifier in the atrium of the human heart. The compounds are therefore suitable for use as novel antiarrhythmic agents for the treatment and prophylaxis of atrial arrhythmias (e.g., atrial fibrillation (AF) or atrial flutter).

  本发明涉及具有式I的蒽酰胺，其中R(1)至R(7)具有本文中指示的含义，其制备方法，它们作为药物的用途，以及含有它们的药物制剂。这些化合物作用于Kv1.5钾通道，抑制一种被称为人类心房中超快速激活延迟整流器的钾电流。因此，这些化合物适用于作为新型抗心律失常药物，用于治疗和预防心房心律失常（例如心房颤动（AF）或心房扑动）。
• Synthesis, characterization and antimicrobial properties of lipophilic palladium complexes bearing iminopyridine ligands
  作者：Patrick T. Gormley、B. Ninh Khuong、Courtney M. Dickie、Ashley M. Taweel、Heather L. Blundon、Josée-Marie E. J. Melanson、Adam F. LeBlanc、Tara S. Murphy、Curran G. Tompkins、Christopher M. Vogels、Andreas Decken、Felix J. Baerlocher、Tyson J. MacCormack、Stephen A. Westcott

  DOI：10.1007/s11243-015-9977-3

  日期：2015.11

  The reaction of [PdCl2(η2-coe)]2 (coe = cis-cyclooctene) with nine lipophilic iminopyridine ligands (NN′, 1a–i) afforded the corresponding metal complexes cis-[PdCl2(NN′)] (2a–i) with concomitant loss of the labile coe ligands. All iminopyridine complexes were characterized by physicochemical and spectroscopic methods. The molecular structures of two complexes, 2a and 2b, were determined by single

  [PdCl2(η2-coe)]2 (coe = cis-cyclooctene) 与九个亲脂性亚氨基吡啶配体 (NN', 1a-i) 反应得到相应的金属配合物 cis-[PdCl2(NN')] (2a-i ) 伴随着不稳定的 coe 配体的丢失。所有亚氨基吡啶配合物均通过物理化学和光谱方法表征。通过单晶 X 射线衍射研究确定了两种配合物 2a 和 2b 的分子结构。测试了所有复合物的潜在抗真菌和抗菌活性。
• ANTHRANILAMIDES AND METHODS OF THEIR USE
  申请人：Brendel Joachim

  公开号：US20070117807A1

  公开（公告）日：2007-05-24

  The present invention is related to a process for preparing anthranilamides of formula I, in which R(1) to R(7) have the meanings indicated herein, a process for their preparation, their use as medicaments, and pharmaceutical preparations containing them. The compounds act on the Kv1.5 potassium channel and inhibit a potassium current which is referred to as the ultra-rapidly activating delayed rectifier in the atrium of the human heart. The compounds are therefore suitable for use as novel antiarrhythmic agents for the treatment and prophylaxis of atrial arrhythmias (e.g., atrial fibrillation (AF) or atrial flutter).

  本发明涉及一种制备式I的蒽酰胺的方法，其中R（1）至R（7）具有本文中所示的含义，其制备方法，作为药物的使用以及含有它们的制药制剂。该化合物对Kv1.5钾通道产生作用，并抑制被称为人类心房中超快速激活延迟整流器的钾电流。因此，该化合物适用于作为新型抗心律失常剂用于治疗和预防心房心律失常（例如心房颤动（AF）或心房扑动）。
• POLYMER COATING COMPRISING 2-METHOXYETHYL ACRYLATE UNITS SYNTHESIZED BY SURFACE-INITIATED ATOM TRANSFER RADICAL POLYMERIZATION
  申请人：Technical University of Denmark

  公开号：EP2453942B1

  公开（公告）日：2014-08-13